Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Prostate MR: pitfalls and benign lesions.

Chatterjee A, Thomas S, Oto A.

Abdom Radiol (NY). 2019 Nov 8. doi: 10.1007/s00261-019-02302-x. [Epub ahead of print] Review.

PMID:
31705249
2.

Benign Conditions That Mimic Prostate Carcinoma: MR Imaging Features with Histopathologic Correlation.

Kitzing YX, Prando A, Varol C, Karczmar GS, Maclean F, Oto A.

Radiographics. 2016 Jan-Feb;36(1):162-75. doi: 10.1148/rg.2016150030. Epub 2015 Nov 20. Review.

3.

Multiparametric magnetic resonance imaging characteristics of normal, benign and malignant conditions in the prostate.

De Visschere PJ, Vral A, Perletti G, Pattyn E, Praet M, Magri V, Villeirs GM.

Eur Radiol. 2017 May;27(5):2095-2109. doi: 10.1007/s00330-016-4479-z. Epub 2016 Aug 4.

PMID:
27491874
4.

MRI-Ultrasound Fusion Targeted Biopsy of Prostate Imaging Reporting and Data System Version 2 Category 5 Lesions Found False-Positive at Multiparametric Prostate MRI.

Sheridan AD, Nath SK, Aneja S, Syed JS, Pahade J, Mathur M, Sprenkle P, Weinreb JC, Spektor M.

AJR Am J Roentgenol. 2018 May;210(5):W218-W225. doi: 10.2214/AJR.17.18680. Epub 2018 Feb 28.

PMID:
29489409
5.

An update of pitfalls in prostate mpMRI: a practical approach through the lens of PI-RADS v. 2 guidelines.

Panebianco V, Giganti F, Kitzing YX, Cornud F, Campa R, De Rubeis G, Ciardi A, Catalano C, Villeirs G.

Insights Imaging. 2018 Feb;9(1):87-101. doi: 10.1007/s13244-017-0578-x. Epub 2017 Oct 23. Review.

6.

The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel.

Muller BG, Fütterer JJ, Gupta RT, Katz A, Kirkham A, Kurhanewicz J, Moul JW, Pinto PA, Rastinehad AR, Robertson C, de la Rosette J, Sanchez-Salas R, Jones JS, Ukimura O, Verma S, Wijkstra H, Marberger M.

BJU Int. 2014 Feb;113(2):218-27. doi: 10.1111/bju.12243. Epub 2013 Nov 13.

7.

Improved detection of anterior fibromuscular stroma and transition zone prostate cancer using biparametric and multiparametric MRI with MRI-targeted biopsy and MRI-US fusion guidance.

Radtke JP, Boxler S, Kuru TH, Wolf MB, Alt CD, Popeneciu IV, Steinemann S, Huettenbrink C, Bergstraesser-Gasch C, Klein T, Kesch C, Roethke M, Becker N, Roth W, Schlemmer HP, Hohenfellner M, Hadaschik BA.

Prostate Cancer Prostatic Dis. 2015 Sep;18(3):288-96. doi: 10.1038/pcan.2015.29. Epub 2015 Jun 16.

PMID:
26078202
8.

Feasibility of Multiparametric Magnetic Resonance Imaging of the Prostate at 7 T.

Lagemaat MW, Philips BW, Vos EK, van Uden MJ, Fütterer JJ, Jenniskens SF, Scheenen TW, Maas MC.

Invest Radiol. 2017 May;52(5):295-301. doi: 10.1097/RLI.0000000000000342.

PMID:
28002239
9.

Central zone lesions on magnetic resonance imaging: Should we be concerned?

Tan WP, Mazzone A, Shors S, Antoine N, Ekbal S, Khare N, McKiel C, Pessis D, Deane L.

Urol Oncol. 2017 Jan;35(1):31.e7-31.e12. doi: 10.1016/j.urolonc.2016.08.006. Epub 2016 Sep 28.

PMID:
27692837
10.

18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer: Correlation With Multiparametric MRI and Histopathology.

Turkbey B, Mena E, Lindenberg L, Adler S, Bednarova S, Berman R, Ton AT, McKinney Y, Eclarinal P, Hill C, Afari G, Bhattacharyya S, Mease RC, Merino MJ, Jacobs PM, Wood BJ, Pinto PA, Pomper MG, Choyke PL.

Clin Nucl Med. 2017 Oct;42(10):735-740. doi: 10.1097/RLU.0000000000001804.

11.

In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy?

Salami SS, Ben-Levi E, Yaskiv O, Ryniker L, Turkbey B, Kavoussi LR, Villani R, Rastinehad AR.

BJU Int. 2015 Apr;115(4):562-70. doi: 10.1111/bju.12938.

12.

Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen.

Radtke JP, Schwab C, Wolf MB, Freitag MT, Alt CD, Kesch C, Popeneciu IV, Huettenbrink C, Gasch C, Klein T, Bonekamp D, Duensing S, Roth W, Schueler S, Stock C, Schlemmer HP, Roethke M, Hohenfellner M, Hadaschik BA.

Eur Urol. 2016 Nov;70(5):846-853. doi: 10.1016/j.eururo.2015.12.052. Epub 2016 Jan 19.

PMID:
26810346
13.

Magnetic resonance imaging in prostate cancer detection and management: a systematic review.

Monni F, Fontanella P, Grasso A, Wiklund P, Ou YC, Randazzo M, Rocco B, Montanari E, Bianchi G.

Minerva Urol Nefrol. 2017 Dec;69(6):567-578. doi: 10.23736/S0393-2249.17.02819-3. Epub 2017 May 8. Review.

14.

Can 3-Tesla pelvic phased-array multiparametric MRI avoid unnecessary repeat prostate biopsy in patients with PSA < 10 ng/mL?

Pepe P, Garufi A, Priolo G, Pennisi M.

Clin Genitourin Cancer. 2015 Feb;13(1):e27-30. doi: 10.1016/j.clgc.2014.06.013. Epub 2014 Jun 21.

PMID:
25081324
15.

Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.

Brizmohun Appayya M, Sidhu HS, Dikaios N, Johnston EW, Simmons LA, Freeman A, Kirkham AP, Ahmed HU, Punwani S.

Br J Radiol. 2018 Feb;91(1083):20170645. doi: 10.1259/bjr.20170645. Epub 2017 Dec 15.

16.

Follow-up of negative MRI-targeted prostate biopsies: when are we missing cancer?

Gold SA, Hale GR, Bloom JB, Smith CP, Rayn KN, Valera V, Wood BJ, Choyke PL, Turkbey B, Pinto PA.

World J Urol. 2019 Feb;37(2):235-241. doi: 10.1007/s00345-018-2337-0. Epub 2018 May 21. Review.

PMID:
29785491
17.

Multiparametric MRI of the anterior prostate gland: clinical-radiological-histopathological correlation.

Moosavi B, Flood TA, Al-Dandan O, Breau RH, Cagiannos I, Morash C, Malone SC, Schieda N.

Clin Radiol. 2016 May;71(5):405-17. doi: 10.1016/j.crad.2016.01.002. Epub 2016 Feb 14. Review.

PMID:
26888762
18.

Volumetric and Voxel-Wise Analysis of Dominant Intraprostatic Lesions on Multiparametric MRI.

Lee J, Carver E, Feldman A, Pantelic MV, Elshaikh M, Wen N.

Front Oncol. 2019 Jul 5;9:616. doi: 10.3389/fonc.2019.00616. eCollection 2019.

19.

Stratification of the aggressiveness of prostate cancer using pre-biopsy multiparametric MRI (mpMRI).

Dwivedi DK, Kumar R, Bora GS, Thulkar S, Sharma S, Gupta SD, Jagannathan NR.

NMR Biomed. 2016 Mar;29(3):232-8. doi: 10.1002/nbm.3452. Epub 2016 Jan 5.

PMID:
26730884
20.

Prebiopsy multiparametric MRI-based risk score for predicting prostate cancer in biopsy-naive men with prostate-specific antigen between 4-10 ng/mL.

Dwivedi DK, Kumar R, Dwivedi AK, Bora GS, Thulkar S, Sharma S, Gupta SD, Jagannathan NR.

J Magn Reson Imaging. 2018 May;47(5):1227-1236. doi: 10.1002/jmri.25850. Epub 2017 Sep 4.

PMID:
28872226

Supplemental Content

Support Center